Efficacy and Safety of Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Adult Obese Patients: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
Latest Information Update: 05 May 2022
At a glance
- Drugs Lorcaserin (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Kanion Huawe Pharmaceutical
Most Recent Events
- 29 Apr 2022 Status changed from suspended to discontinued. Reason the study was stopped: Reassess safety risks and benefits.
- 09 Apr 2020 Status changed from recruiting to suspended.
- 26 Sep 2019 Status changed from not yet recruiting to recruiting.